|Day Low/High||23.94 / 23.99|
|52 Wk Low/High||4.37 / 10.07|
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the...
Jim Cramer highlights bank, health-care companies reporting next week and what to watch.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ARIAD...
Animal health and oncology deal activity is heating up in 2017.
This year's profitable trends look to persist into 2017.
Going into earnings what the market needs now is more negativity, Cramer says.
McDonald's announces its intentions to sell its China business to a group including Carlyle Group as Apple celebrates the iPhone's 10th birthday. Plus Trump's latest meetings.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.
Put a charge in your portfolio this week.
Shares of Ariad Pharmaceuticals soared Monday after Japan's Takeda Pharmaceutical offered to buy the leukemia drug maker.
Stocks trade mostly lower with the Dow Jones Industrial Average taking a pause in its race toward 20,000.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ARIAD Pharmaceuticals Inc , where a total of 23,103 contracts have traded so far, representing approximately 2.3 million underlying shares. That amounts to about 67.5% of ARIA's average daily trading volume over the past month of 3.4 million shares.
Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.
Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.
With poor breadth and money managers hiding in large-caps, I am being cautious, right now.
Deals, though, weren't the only mover of share prices.
Stock futures mostly lower Monday morning amid a slump in crude oil prices.
ARIAD Pharmaceuticals (NASDAQ:ARIA) ("ARIAD") today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") under which Takeda will acquire all of...
Takeda Pharmaceutical Company Limited (TSE:4502) ("Takeda") and ARIAD Pharmaceuticals, Inc.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.